CD274 and non-small cell lung carcinoma: The randomized phase III BR31 trial evaluated 1 year of adjuvant durvalumab (PD-L1 inhibitor) versus placebo in this same setting of radically resected stage IB (≥4 cm), II or IIIA NSCLC (TNM7).